Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	recommended dose	2 years	recommended dose of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab
Primary	activity	3 years	activity of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of overaal response rate per RECIST v1.1.
Secondary	quality of life for cancer patients	3 years	quality of life as measured by EORTC QLQ-C30 questionnaire.
Secondary	quality of life for colorectal cancer patients	3 years	quality of life as measured by EORTC QLQ-CR29 questionnaire.
Secondary	quality of life for dimensions health	3 years	quality of life as measured by EuroQol EQ-5D questionnaire.
Secondary	survival	3 years	efficacy of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab in terms of progression-free survival and overall survival
Other	bioavailability	2 years	Absolute and relative bioavailability of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Steady state concentration	2 years	Steady state concentration of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Therapeutic index	2 years	Therapeutic index of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Volume of distribution	2 years	Volume of distribution of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Half-life	2 years	Plasma half-life of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.
Other	Clearance	2 years	Clearance of the combination trifluridine/tipiracil plus capecitabine plus bevacizumab.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04564898/registered

API reference For AI assistants